PCOP: Pharmacopeia, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PCOP: Pharmacopeia, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	10/16/2007 6:23:52 AM
	Read Replies (1) of 180

PCOP gains an earlystage clinical drug candidate with a minimal increase in near-term burn: Pharmacopeia Buys SARM Program From Bristol-Myers Squibb By Joe Melvin Last Update: 7:27 AM ET Oct 15, 2007 marketwatch.com PCOP said Monday it has licensed a selective androgen receptor modulator (SARM) program from Bristol-Myers Squibb Co. (BMY) The program includes a lead compound in Phase 1 clinical development and back-up compounds. Pharmacopeia, which develop novel small molecule therapeutics, said PS178990 is a non-steroidal selective androgen receptor modulator, or SARM, which is designed to provide the benefits of testosterone without its unwanted side effects on the prostate. A Phase 1 single ascending dose study has already been completed. SARM agonists provide a potential novel treatment for muscle wasting associated with a number of serious chronic and acute medical conditions such as surgical and severe burn recovery, end-stage renal disease and cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next